Article Text

Download PDFPDF
High frequency of APOB gene mutations causing familial hypobetalipoproteinaemia in patients of Dutch and Spanish descent
  1. S W Fouchier1,
  2. R R Sankatsing1,
  3. J Peter1,
  4. S Castillo2,
  5. M Pocovi2,
  6. R Alonso3,
  7. J J P Kastelein1,
  8. J C Defesche1
  1. 1Department of Vascular Medicine, Academic Medical Center at the University of Amsterdam, Amsterdam, The Netherlands
  2. 2Department of Biochemistry, Cellular Biology Universidad de Zaragoza, Zaragoza, Spain
  3. 3Lipid Unit Research, Fundacion Jimenez Diaz, Madrid, Spain
  1. Correspondence to:
 Dr J C Defesche
 Department of Vascular Medicine G1–113, Academic Medical Center, University of Amsterdam, P.O. Box 22660, 1100 DD Amsterdam, The Netherlands; j.defescheamc.uva.nl

Abstract

Background: Familial hypobetalipoproteinaemia (FHBL) is an autosomal co-dominant hereditary disorder of lipoprotein metabolism characterised by decreased low density lipoprotein (LDL) cholesterol and apolipoprotein B (APOB) plasma levels. High levels of plasma APOB and LDL cholesterol are strong predictors for risk of cardiovascular disease (CVD), while individuals with low APOB and LDL cholesterol levels are thought to have lower than average risk for CVD, and in fact, heterozygous FHBL patients appear to be asymptomatic.

Methods: Rather than identifying truncated APOB proteins in plasma fractions separated by gel electrophoresis, which will miss any mutations in proteins smaller than 30 kb, we analysed the APOB gene directly, using PCR.

Results: We identified nine different mutations, six of which are novel. Each mutation showed complete co-segregation with the FHBL phenotype in the families, and statistically significant differences between carriers and non-carriers were found for plasma total, LDL, and HDL cholesteroll, triglycerides, and APOB levels, but not for APOA1 levels. All carriers of an APOB mutation were completely free from CVD.

Conclusions: Prolonged low levels of LDL cholesterol and elevated levels of HDL cholesterol may reduce the progression of atherosclerotic disease, but this has not been unequivocally shown that this is indeed the case in individuals with FHBL, and is the subject of a current study.

  • FHBL
  • Familial hypobetalipoproteinaemia
  • apolipoprotein B mutations

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Footnotes

  • Competing interest: none declared